Literature DB >> 2933380

In-vitro evaluation of cefpirome (HR 810), teicoplanin and four other antimicrobials against enterococci.

P H Chandrasekar, S Price, D P Levine.   

Abstract

In-vitro activities of cefpirome (HR 810), a fourth generation cephalosporin, and teicoplanin were compared with those of ampicillin, piperacillin, and vancomycin against 56 clinical isolates of enterococci. Cefpirome had good activity with the MIC90 and MBC90 being 4 and 16 mg/l. Ampicillin and piperacillin had MBC90 of 4 and 16 mg/l. Teicoplanin was extremely active with the MIC90 being 1.6 mg/l while vancomycin had poor cidal activity with the MBC90 being 16 mg/l. A decrease in activity of cefpirome was noted when the inoculum size was increased from 10(3) to 10(7) organisms per ml. Synergy was demonstrated against most Streptococcus faecium isolates with a combination of cefpirome and gentamicin or piperacillin. Against Str. faecalis, with a similar combination, synergy was seen in less than 50% isolates. No antagonism was noted with any of the antibiotic combinations.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2933380     DOI: 10.1093/jac/16.2.179

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

1.  In vitro activity of cefpirome (HR810) against Enterococcus species.

Authors:  P F Wheat; R C Spencer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-03       Impact factor: 3.267

2.  Problems with the disk diffusion test for detection of vancomycin resistance in enterococci.

Authors:  J M Swenson; B C Hill; C Thornsberry
Journal:  J Clin Microbiol       Date:  1989-09       Impact factor: 5.948

Review 3.  Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  D M Campoli-Richards; R N Brogden; D Faulds
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

4.  Comparative in vitro activity of cefpirome (HR 810) against gram-positive isolates from cancer patients.

Authors:  K V Rolston; G P Bodey
Journal:  Infection       Date:  1986 May-Jun       Impact factor: 3.553

Review 5.  Endophthalmitis caused by Gram-positive organisms with reduced vancomycin susceptibility: literature review and options for treatment.

Authors:  Nidhi Relhan; Thomas A Albini; Avinash Pathengay; Ajay E Kuriyan; Darlene Miller; Harry W Flynn
Journal:  Br J Ophthalmol       Date:  2015-12-23       Impact factor: 4.638

6.  Recovery of resistant enterococci during vancomycin prophylaxis.

Authors:  A H Kaplan; P H Gilligan; R R Facklam
Journal:  J Clin Microbiol       Date:  1988-06       Impact factor: 5.948

7.  Teicoplanin in the treatment of skin and soft tissue infections: results of a multicentre study.

Authors:  E Lang; M Földes; S Marghescu
Journal:  Infection       Date:  1991 May-Jun       Impact factor: 3.553

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.